Development of a Long Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP 1R Agonists for the Treatment of Obesity Bioconjugate Chemistry Dosing Cagri Peptide : r cagrilintide Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Weight loss with GLP 1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine Novo Nordisk A S: CagriSema demonstrated 23% weight loss in an open label head to head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved